Found 1 Presentation For Request "1202P"
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
- Didier Debieuvre (Mulhouse, France)
Abstract
Background
Crizotinib is the first tyrosine kinase inhibitor authorized for the treatment of aNSCLC ALK+ or ROS1+, regardless of lines. Real-world (RW) data is scarce for these populations.
Methods
We conducted a non-interventional ambispective multicentric study on aNSCLC ALK+ or ROS1+ treated by crizotinib in collaboration with the CPHG (French College of General Hospital Respiratory Physician). The aim was first to describe patient’s characteristics, and second to evaluate effectiveness and safety of crizotinib in a RW setting in General Hospital in France.
Results
73 patients were included: 51 patients ALK+, 22 patients ROS1+. Median age was 65 -year-old [Q1-Q3: 52.0; 73.0], 45 (63.4%) female, 52 (82.5%) patients with ECOG < 2
Conclusions
Our results are consistent with other RW in terms of effectiveness and safety. Crizotinib was effective in both ALK+ and ROS1+ aNSCLC in a real-life setting with no new safety concerns.
Clinical trial identification
NCT03718117.
Legal entity responsible for the study
Pfizer SAS.
Funding
Pfizer.
Disclosure
D. Debieuvre: Financial Interests, Personal and Institutional, Principal Investigator: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer. J. Grelier: Other, Personal, Full or part-time Employment: Pfizer. J. Le Treut: Financial Interests, Personal and Institutional, Advisory Board: Roche; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: Pfizer; Financial Interests, Personal and Institutional, Advisory Board: BMS; Financial Interests, Personal and Institutional, Advisory Board: MSF. All other authors have declared no conflicts of interest.